Misplaced Pages

Revision as of 02:46, 17 June 2013

Template:Redirect4

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Methamphetamine" – news · newspapers · books · scholar · JSTOR (May 2013) (Learn how and when to remove this message)

Methamphetamine

Clinical data
Other names	Desoxyephedrine Methamfetamine Pervitin Anadrex Methedrine Methylamphetamine Syndrox Desoxyn
Dependence liability	High
Routes of administration	Medical: Ingestion Recreational: Ingestion, Intravenous, Insufflation, Inhalation, Suppository
ATC code	N06BA03 (WHO)
Legal status
Legal status	AU: S8 (Controlled drug) CA: Schedule I US: Schedule II Class A(NZ) Schedule 5(SA) Injectable: Class A, Oral: A(UK)
Pharmacokinetic data
Bioavailability	62.7% oral; 79% nasal; 90.3% smoked; 99% rectally; 100% IV
Metabolism	Hepatic
Elimination half-life	9–12 hours
Excretion	Renal
Identifiers
IUPAC name N-methyl-1-phenylpropan-2-amine
CAS Number	537-46-2
PubChem CID	1206
DrugBank	DB01577
ChemSpider	1169
UNII	44RAL3456C
KEGG	D08187
ChEBI	CHEBI:6809
ChEMBL	ChEMBL1201201
CompTox Dashboard (EPA)	DTXSID8037128
ECHA InfoCard	100.007.882
Chemical and physical data
Formula	C10H15N
Molar mass	149.2337 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES N(C(Cc1ccccc1)C)C
InChI InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3 Key:MYWUZJCMWCOHBA-UHFFFAOYSA-N
(what is this?)  (verify)

Methamphetamine (USAN) /ˌmɛθæmˈfɛtəmiːn/, also known as metamfetamine (INN), meth, ice, clouds crystal, glass, tik, N-methylamphetamine, methylamphetamine, and desoxyephedrine, is a psychostimulant of the phenethylamine and amphetamine class of psychoactive drugs.

Methamphetamine occurs in two enantiomers, dextrorotary and levorotary; dextromethamphetamine possesses the well-known psychostimulant effects of the drug, while levomethamphetamine is CNS-inactive. Although rarely prescribed, methamphetamine hydrochloride is approved by the U.S. Food and Drug Administration (FDA) for the treatment of attention deficit hyperactivity disorder and obesity under the trade name Desoxyn.

Illicitly, methamphetamine may be sold either as pure dextromethamphetamine or in a racemic mixture. Both dextromethamphetamine and racemic methamphetamine are Schedule II controlled substances in the United States, and similarly the production, distribution, sale, and possession of methamphetamine is restricted or illegal in many jurisdictions. Internationally, methamphetamine has been placed in Schedule II of the United Nations Convention on Psychotropic Substances treaty.

Contrary to popular misconception, methamphetamine in both powder and crystal form is a hydrochloride salt. The freebase form of methamphetamine (as well as amphetamine) is an oily liquid. The misconception started with the fact that heroin and cocaine are injected or snorted as salts, but they are smoked in freebase form. See also: crack cocaine.

In low dosages, methamphetamine can increase alertness, concentration, and energy in fatigued individuals. In higher doses, it can induce mania with accompanying euphoria, feelings of self-esteem and increased libido. Methamphetamine has a high potential for abuse and addiction, activating the psychological reward system by triggering a cascading release of dopamine in the brain characterized as Amphetamine/Stimulant psychosis.

Chronic abuse may also lead to post-withdrawal syndrome, a result of methamphetamine-induced neurotoxicity to dopaminergic neurons. Post-withdrawal syndrome can persist beyond the withdrawal period for months, and sometimes up to a year. In addition to psychological harm, physical harm – primarily consisting of cardiovascular damage – may occur with chronic use or acute overdose.

Uses

Methamphetamine has found use as both a medicinal and recreational drug.

Medical use

In United States, Methamphetamine has been approved by the Food and Drug Administration (FDA) in treating ADHD and exogenous obesity (obesity originating from factors outside of the patient's control) in both adults and children.

Methamphetamine is a Schedule II drug in the United States and is sold under the name Desoxyn trademarked by the Danish pharmaceutical company Lundbeck.

Desoxyn may be prescribed off-label for the treatment of narcolepsy and treatment-resistant depression.

Recreational use

Methamphetamine is used as a recreational drug for its euphoric and stimulant properties.

Effects

Physical

Physical effects can include anorexia, hyperactivity, dilated pupils, flushed skin, excessive sweating, restlessness, dry mouth and bruxism (leading to "meth mouth"), headache, accelerated heartbeat, slowed heartbeat, irregular heartbeat, rapid breathing, high blood pressure, low blood pressure, high body temperature, diarrhea, constipation, blurred vision, dizziness, twitching, insomnia, numbness, palpitations, tremors, dry and/or itchy skin, acne, pallor, and – with chronic and/or high doses – convulsions, heart attack, stroke, and death.

Psychological

Psychological effects can include euphoria, anxiety, increased libido, alertness, concentration, increased energy, increased self-esteem, self-confidence, sociability, irritability, aggressiveness, psychosomatic disorders, psychomotor agitation, dermatillomania (compulsive skin picking), hair pulling, delusions of grandiosity, hallucinations, excessive feelings of power and invincibility, repetitive and obsessive behaviors, paranoia, and – with chronic use and/or high doses – amphetamine psychosis.

Withdrawal

Withdrawal symptoms of methamphetamine primarily consist of fatigue, depression, and increased appetite. Symptoms may last for days with occasional use and weeks or months with chronic use, with severity dependent on the length of time and the amount of methamphetamine used. Withdrawal symptoms may also include anxiety, irritability, headaches, agitation, restlessness, excessive sleeping, vivid or lucid dreams, deep REM sleep, and suicidal ideation.

Long-term

Methamphetamine use has a high association with depression and suicide as well as serious heart disease, amphetamine psychosis, anxiety, and violent behaviors. Methamphetamine also has a very high addiction risk.

Methamphetamine is not directly neurotoxic but long-term use can have neurotoxic side-effects. Its use is associated with an increased risk of Parkinson's disease due to the fact that uncontrolled dopamine release is neurotoxic. Long-term dopamine upregulation occurring as a result of Methamphetamine abuse can cause neurotoxicity, which is believed to be responsible for causing persisting cognitive deficits, such as memory loss, impaired attention, and decreased executive function. Similar to the neurotoxic effects on the dopamine system, methamphetamine can also result in neurotoxicity to the serotonin system.

As a result of methamphetamine-induced neurotoxicity to dopaminergic neurons, chronic abuse may also lead to post acute withdrawals which persist beyond the withdrawal period for months, and even up to a year. A study performed on female Japanese prison inmates suffering from methamphetamine addiction showed that 49% experienced "flashbacks" afterward and 21% experienced a psychosis resembling schizophrenia which persisted for longer than six months post-methamphetamine use; this amphetamine psychosis could be resistant to traditional treatment. Other studies in Japan show that those who experience methamphetamine-induced psychosis are much more likely to experience psychotic symptoms again if they use methamphetamine. In addition to psychological harm, physical harm – primarily consisting of cardiovascular damage – may occur with chronic use or acute overdose.

Tolerance

As with other amphetamines, tolerance to methamphetamine is not completely understood but is known to be sufficiently complex that it cannot be explained by any single mechanism. The extent of tolerance and the rate at which it develops vary widely between individuals, and even within one person. It is highly dependent on dosage, duration of use, and frequency of administration. Tolerance to the awakening effect of amphetamines does not readily develop, making them suitable for the treatment of narcolepsy.

Short-term tolerance can be caused by depleted levels of neurotransmitters within the synaptic vesicles available for release into the synaptic cleft following subsequent reuse (tachyphylaxis). Short-term tolerance typically lasts until neurotransmitter levels are fully replenished; because of the toxic effects on dopaminergic neurons, this can be greater than 2–3 days. Prolonged overstimulation of dopamine receptors caused by methamphetamine may eventually cause the receptors to downregulate in order to compensate for increased levels of dopamine within the synaptic cleft. To compensate, larger quantities of the drug are needed in order to achieve the same level of effects.

Reverse tolerance or sensitization can also occur. The effect is well established, but the mechanism is not well understood.

Adverse effects

Addiction

Methamphetamine is highly addictive. While the withdrawal itself may not be dangerous, withdrawal symptoms are common with heavy use and relapse is common.

Methamphetamine-induced hyperstimulation of pleasure pathways can lead to anhedonia months after use has been discontinued. Investigation of treatments targeting dopamine signalling such as bupropion, or psychological treatments that raise hedonic tone, such as behavioral activation therapy, have been suggested. It is possible that daily administration of the amino acids L-tyrosine and L-5HTP/tryptophan can aid in the recovery process by making it easier for the body to reverse the depletion of dopamine, norepinephrine, and serotonin. Although studies involving the use of these amino acids have shown some success, this method of recovery has not been shown to be consistently effective.

It is shown that taking ascorbic acid prior to using methamphetamine may help reduce acute toxicity to the brain, as rats given the human equivalent of 5–10  grams of ascorbic acid 30 minutes prior to methamphetamine dosage had toxicity mediated, yet this will likely be of little avail in solving the other serious behavioral problems associated with methamphetamine use and addiction that many users experience. Large doses of ascorbic acid also lower urinary pH, reducing methamphetamine's elimination half-life and thus decreasing the duration of its actions.

To combat addiction, doctors are beginning to use other forms of stimulants such as dextroamphetamine, the dextrorotatory (right-handed) isomer of the amphetamine molecule, to break the addiction cycle in a method similar to the use of methadone in the treatment of heroin addicts. There are no publicly available drugs comparable to naloxone, which blocks opiate receptors and is therefore used in treating opiate dependence, for use with methamphetamine problems. However, experiments with some monoamine reuptake inhibitors such as indatraline have been successful in blocking the action of methamphetamine. There are studies indicating that fluoxetine, bupropion and imipramine may reduce craving and improve adherence to treatment. Research has also suggested that modafinil can help addicts quit methamphetamine use, as can Topiramate.

Methamphetamine addiction is one of the most difficult forms of addictions to treat. Bupropion, aripiprazole, and baclofen have been employed to treat post-withdrawal cravings, although the success rate is low. Modafinil is somewhat more successful, but this is a Class IV scheduled drug. Ibogaine has been used with success in Europe, where it is a Class I drug and available only for scientific research. Mirtazapine has been reported useful in some small-population studies.

As the phenethylamine phentermine is a constitutional isomer of methamphetamine, it has been suggested that it may be effective in treating methamphetamine addiction. Phentermine is a central nervous system stimulant that acts on dopamine and norepinephrine. When comparing (+)-amphetamine, (+/-)-ephedrine, and phentermine, one key difference among the three drugs is their selectivity for norepinephrine (NE) release vs. dopamine (DA) release. The NE/DA selectivity ratios for these drugs as determined in vitro are (+/-)-ephedrine (18.6) > phentermine (6.7) > (+)-amphetamine (3.5).

Abrupt interruption of chronic methamphetamine use results in the withdrawal syndrome in almost 90% of the cases.

The mental depression associated with methamphetamine withdrawal lasts longer and is more severe than that of cocaine withdrawal.

Meth mouth

Methamphetamine users and addicts may lose their teeth abnormally quickly, a condition informally known as meth mouth. According to the American Dental Association, meth mouth "is probably caused by a combination of drug-induced psychological and physiological changes resulting in xerostomia (dry mouth), extended periods of poor oral hygiene, frequent consumption of high-calorie, carbonated beverages and bruxism (teeth grinding and clenching)". Some reports have also speculated that the caustic nature of the drug is a contributing factor. Methamphetamine also has the potential to cause excessive cigarette smoking for users already smoking. This combined with the methamphetamine can perpetuate the "meth mouth". Similar, though far less severe, symptoms have been reported in clinical use of regular amphetamine, where effects are not exacerbated by extended periods of poor oral hygiene.

Public health issues

Short-term exposure to high concentrations of chemical vapors that may exist in black market methamphetamine laboratories can cause severe health problems or even result in death. Exposure to these substances can occur from volatile air emissions, spills, fires, and explosions. Such methamphetamine labs are often discovered when fire fighters respond to a blaze. Methamphetamine cooks, their families, and first responders are at highest risk of acute health effects from chemical exposure, including lung damage and chemical burns to the body. Following a seizure of a methamphetamine lab, there is often a low exposure risk to chemical residues, however this contamination should be sanitized. Chemical residues and lab wastes that are left behind at a former methamphetamine lab can result in severe health problems for people who use the property, therefore local health departments should thoroughly assess the property for hazards prior to allowing it to be reinhabited, especially by children. Those seeking home ownership in heavy meth use areas should be especially careful while house hunting and be sure to have properties inspected before purchasing.

Pregnancy and breastfeeding

Methamphetamine present in a mother's bloodstream passes through the placenta to a fetus, and is also secreted into breast milk. Infants born to methamphetamine-abusing mothers were found to have a significantly smaller gestational age-adjusted head circumference and birth weight measurements. Methamphetamine exposure was also associated with neonatal withdrawal symptoms of agitation, vomiting and tachypnea. This withdrawal syndrome is relatively mild and only requires medical intervention in approximately 4% of cases.

Risk of sexually transmitted disease

Men who use methamphetamine, cocaine, MDMA, and ketamine, are twice as likely to have unprotected sex than those who do not use such drugs, according to British research. American psychologist Perry N. Halkitis performed an analysis using data collected from community-based participants among gay and bisexual men to examine the associations between their methamphetamine use and sexual risk taking behaviors. Methamphetamine use was found to be related to higher frequencies of unprotected sexual intercourse in both HIV-positive and unknown casual partners in the study population. The association between methamphetamine use and unprotected acts were also more pronounced in HIV-positive participants. These findings suggested that methamphetamine use and engagement in unprotected anal intercourse are co-occurring risk behaviors that potentially heighten the risk of HIV transmission among gay and bisexual men. Methamphetamine allows users of both sexes to engage in prolonged sexual activity, which may cause genital sores and abrasions. Methamphetamine can also cause sores and abrasions in the mouth via bruxism (teeth clenching and grinding), which can turn typically low-risk sex acts, such as oral sex, into high-risk sexual activity. As with the injection of any drug, if a group of users share a common needle, blood-borne diseases, such as HIV or hepatitis, can be transmitted. The level of needle sharing among methamphetamine users is similar to that among other drug injection users.

Pharmacokinetics

Following oral administration, methamphetamine is readily absorbed into the bloodstream, with peak plasma concentrations achieved in approximately 3.13 to 6.3 hours post ingestion. The amphetamine metabolite peaks at 10 to 24 hours. Methamphetamine is also well absorbed following inhalation and following intranasal administration. It is distributed to most parts of the body. Methamphetamine is known to produce central effects similar to the other stimulants, but at smaller doses, with fewer peripheral effects. Methamphetamine's high lipophilicity also allows it to cross the blood brain barrier faster than other stimulants, where it is more stable against degradation by monoamine oxidase (MAO).

Methamphetamine is metabolized in the liver with the main metabolites being amphetamine (active) and 4-hydroxymethamphetamine (pholedrine); other minor metabolites include 4-hydroxyamphetamine, norephedrine, and 4-hydroxynorephedrine. Other drugs metabolized to amphetamine and methamphetamine include benzphetamine, furfenorex, and famprofazone. Selegiline (marketed as Deprenyl, EMSAM, and others) is metabolized into the less active L-isomer of amphetamine and the inactive L-isomer of methamphetamine. Although only the D-Isomer of selegiline will metabolize into active metabolites, both isomers may cause a positive result for methamphetamine and amphetamine on a drug test, in certain cases.

It is excreted by the kidneys, with the rate of excretion into the urine heavily influenced by urinary pH. Between 30-54% of an oral dose is excreted in urine as unchanged methamphetamine and 10-23% as unchanged amphetamine. Following an intravenous dose, 45% is excreted as unchanged parent drug and 7% amphetamine. The half-life of methamphetamine is variable with a mean value of between 9 and 12 hours.

Detection in biological fluids

Methamphetamine and amphetamine are often measured in urine, sweat or saliva as part of a drug-abuse testing program, in plasma or serum to confirm a diagnosis of poisoning in hospitalized victims, or in whole blood to assist in a forensic investigation of a traffic or other criminal violation or a case of sudden death. Chiral techniques may be employed to help distinguish the source of the drug, whether obtained legally (via prescription) or illicitly, or possibly as a result of formation from a prodrug such as famprofazone or selegiline. Chiral separation is needed to assess the possible contribution of l-methamphetamine (Vicks Inhaler) toward a positive test result. In 2011, researchers at John Jay College of Criminal Justice reported that dietary zinc supplements can mask the presence of methamphetamine and other drugs in urine. Similar claims have been made in web forums on that topic.

Pharmacology

A member of the family of phenethylamines, methamphetamine is chiral, with two isomers, levorotatory and dextrorotatory. The levorotatory form, called levomethamphetamine, is an over-the-counter drug used in inhalers for nasal decongestion. Levomethamphetamine (a levoamphetamine derivative) does not possess any significant central nervous system activity or addictive properties. This article deals only with the dextrorotatory form, called dextromethamphetamine, and the racemic form.

Methamphetamine is a potent central nervous system stimulant that affects neurochemical mechanisms responsible for regulating heart rate, body temperature, blood pressure, appetite, attention, mood and emotional responses associated with alertness or alarming conditions. The acute physical effects of the drug closely resemble the physiological and psychological effects of an epinephrine-provoked fight-or-flight response, including increased heart rate and blood pressure, vasoconstriction (constriction of the arterial walls), bronchodilation, and hyperglycemia (increased blood sugar). Users experience an increase in focus, increased mental alertness, and the elimination of fatigue, as well as a decrease in appetite. It is known to produce central effects similar to the other stimulants, but at smaller doses, with fewer peripheral effects. Methamphetamine's fat solubility also allows it to enter the brain faster than other stimulants, where it is more stable against degradation by monoamine oxidase (MAO).

The methyl group is responsible for the potentiation of effects as compared to the related compound amphetamine, rendering the substance more lipid-soluble, enhancing transport across the blood–brain barrier, and more stable against enzymatic degradation by monoamine oxidase (MAO). Methamphetamine causes the norepinephrine, dopamine, and serotonin (5HT) transporters to reverse their direction of flow. This inversion leads to a release of these transmitters from the vesicles to the cytoplasm and from the cytoplasm to the synapse (releasing monoamines in rats with ratios of about NE:DA = 1:2, NE: 5HT = 1:60), causing increased stimulation of post-synaptic receptors. Methamphetamine also indirectly prevents the reuptake of these neurotransmitters, causing them to remain in the synaptic cleft for a prolonged period (inhibiting monoamine reuptake in rats with ratios of about: NE:DA = 1:2.35, NE:5HT = 1:44.5). Methamphetamine also interacts with TAAR1 to trigger phosphorylation of PKA and PKC, ultimately resulting in the internalization of dopamine transporters. The presynaptic cell is less able to effectively remove dopamine from the synapse. The binding of methamphetamine to TAAR1 also activates adenylyl cyclase, which allows for increased intracellular cAMP. Taken together, the binding of methamphetamine to TAAR1 results in a massive efflux of neurogenic monoamines with a sustained synaptic presence.

Methamphetamine is a potent neurotoxin, shown to cause dopaminergic degeneration. High doses of methamphetamine produce losses in several markers of brain dopamine and serotonin neurons. Dopamine and serotonin concentrations, dopamine and 5HT uptake sites, and tyrosine and tryptophan hydroxylase activities are reduced after the administration of methamphetamine. It has been proposed that dopamine plays a role in methamphetamine-induced neurotoxicity, because experiments that reduce dopamine production or block the release of dopamine decrease the toxic effects of methamphetamine administration. When dopamine breaks down, it produces reactive oxygen species such as hydrogen peroxide. It is likely that the approximate twelvefold increase in dopamine levels and subsequent oxidative stress that occurs after taking methamphetamine mediates its neurotoxicity. The lab of David Sulzer and colleagues at Columbia University developed a technique known as "intracellular patch electrochemistry" to measure concentrations of dopamine in the cytosol, and found massive increases following methamphetamine, leading to the "cytosolic dopamine hypothesis" of neurotoxicity, in which dopamine oxidation, particularly close to synaptic vesicles, produce oxidative stress that in turn leads to exacerbation of autophagy that can destroy axons and dendrites.

Recent research published in the Journal of Pharmacology And Experimental Therapeutics (2007) indicates that methamphetamine binds to and activates a G protein-coupled receptor called TAAR1. TAARs are a newly discovered receptor family whose members are activated by a number of amphetamine-like molecules called trace amines, thyronamines, and certain volatile odorants.

It has been demonstrated that a high core temperature is correlated with an increase in the neurotoxic effects of methamphetamine.

Natural occurrence

Methamphetamine has been reported to occur naturally in Acacia berlandieri, and possibly Acacia rigidula, trees that grow in West Texas. Methamphetamine and amphetamine were long thought to be strictly human-synthesized, but Acacia trees contain these and numerous other psychoactive compounds (e. g., mescaline, nicotine, dimethyltryptamine), and the related compound β-phenethylamine is known to occur from numerous Acacia species. The findings, however, have never been confirmed or repeated, leading some researchers to believe the results were the result of cross-contamination.

Routes of administration

Studies have shown that the subjective pleasure of drug use (the reinforcing component of addiction) is proportional to the rate at which the blood level of the drug increases. These findings suggest the route of administration used affects the potential risk for psychological addiction independently of other risk factors, such as dosage and frequency of use. Intravenous injection is the fastest route of drug administration, causing blood concentrations to rise the most quickly, followed by smoking, suppository (anal or vaginal insertion), insufflation (snorting), and ingestion (swallowing). Ingestion does not produce a rush, an acute transcendent state of euphoria as forerunner to the high experienced with the use of methamphetamine, which is most pronounced with the intravenous route of administration. While the onset of the rush induced by injection can occur in as little as a few seconds, the oral route of administration requires approximately half an hour before the high sets in.

Injection

Injection carries relatively greater risks than other methods of administration. The hydrochloride salt of methamphetamine is soluble in water. Intravenous users may use any dose range, from less than 100 milligrams to over one gram, using a hypodermic needle, although it should be noted that typically street methamphetamine is “cut,” or diluted, with a water-soluble cutting material, which constitutes a significant portion of a given street methamphetamine dose. Intravenous users risk developing pulmonary embolism (PE), a blockage of the main artery of the lung or one of its branches, and commonly develop skin rashes (also known as "speed bumps") or infections at the site of injection. As with the injection of any drug, if a group of users share a common needle without sterilization procedures, blood-borne diseases, such as HIV or hepatitis, can be transmitted.

Smoking

Smoking amphetamines refers to vaporizing it to inhale the resulting fumes, not burning it to inhale the resulting smoke. It is commonly smoked in glass pipes made from glassblown Pyrex tubes and light bulbs. It can also be smoked off aluminium foil, which is heated underneath by a flame. This method is also known as "chasing the white dragon" (whereas smoking heroin is known as "chasing the dragon"). There is little evidence that methamphetamine inhalation results in greater toxicity than any other route of administration. Lung damage has been reported with long-term use, but manifests in forms independent of route (pulmonary hypertension (PH)), or limited to injection users (pulmonary embolism (PE)).

Insufflation

Another popular route of administration to intake methamphetamine is insufflation (snorting). This method allows methamphetamine to be absorbed through the soft tissue of the mucous membrane in the sinus cavity, and then directly into the bloodstream, bypassing first-pass metabolism.

Suppository

Suppository (anal or vaginal insertion) is a less popular method of administration used in the community with comparatively little research into its effects. Information on its use is largely anecdotal with reports of increased sexual pleasure and the effects of the drug lasting longer, though as methamphetamine is centrally active in the brain, these effects are likely experienced through the higher bioavailability of the drug in the bloodstream (second to injection) and the faster onset of action (than insufflation). Nicknames for the route of administration within some methamphetamine communities include a "butt rocket", a "booty bump", "potato thumping", "turkey basting", "plugging", "boofing", "suitcasing", "hooping", "keistering", "shafting", "bumming", and "shelving" (vaginal).

History

Discovery

Shortly after the first synthesis of amphetamine in 1887, methamphetamine was synthesized from ephedrine in 1893 by Japanese chemist Nagai Nagayoshi. The term "methamphetamine" was derived from elements of the chemical structure of this new compound: methyl alpha-methyl phenyl ethyl amine. In 1919, crystallized methamphetamine was synthesized by pharmacologist Akira Ogata via reduction of ephedrine using red phosphorus and iodine.

Military use

One of the earliest uses of methamphetamine was during World War II, when it was used by Axis and Allied forces. The company Temmler produced methamphetamine under the trademark Pervitin and so did the German and Finnish militaries. It was also dubbed "Pilot's chocolate" or "Pilot's salt". It was widely distributed across rank and division, from elite forces to tank crews and aircraft personnel, with many millions of tablets being distributed throughout the war. Its use by German Panzer crews also led to it being known as "Panzerschokolade" ("Panzer chocolate" or "tankers' chocolate"). More than 35 million three-milligram doses of Pervitin were manufactured for the German army and air force between April and July 1940. From 1942 until his death in 1945, Adolf Hitler was given intravenous injections of methamphetamine by his personal physician Theodor Morell. It is possible that it was used to treat Hitler's speculated Parkinson's disease, or that his Parkinson-like symptoms that developed from 1940 onwards resulted from using methamphetamine. In Japan, methamphetamine was sold under the registered trademark of Philopon (ヒロポン hiropon) by Dainippon Pharmaceuticals (present-day Dainippon Sumitomo Pharma ) for civilian and military use. As with the rest of the world at the time, the side effects of methamphetamine were not well studied, and regulation was not seen as necessary. In the 1940s and 1950s the drug was widely administered to Japanese industrial workers to increase their productivity.

Methamphetamine and amphetamine were given to Allied bomber pilots during World War II to sustain them by fighting off fatigue and enhancing focus during long flights. The experiment failed because soldiers became agitated, could not channel their aggression and showed impaired judgment. Rather, dextroamphetamine (Dexedrine) became the drug of choice for American bomber pilots, being used on a voluntary basis by roughly half of the U.S. Air Force pilots during the Persian Gulf War, a practice which came under some media scrutiny in 2003 after a mistaken attack on Canadian troops.

Medical and legal over-the-counter sales

Following the use of amphetamine (such as Benzedrine, introduced 1932) in the 1930s for asthma, narcolepsy, and symptoms of the common cold, in 1943, Abbott Laboratories requested U.S. FDA approval of methamphetamine for treatment of narcolepsy, mild depression, postencephalitic parkinsonism, chronic alcoholism, cerebral arteriosclerosis, and hay fever, which was granted in December 1944.

Sale of the massive postwar surplus of methamphetamine in Europe, North America, and Japan stimulated civilian demand. After World War II, a large Japanese military stockpile of methamphetamine, known by its trademark Philopon, flooded the market. Post-war Japan experienced the first methamphetamine epidemic, which later spread to Guam, the U. S. Marshall Islands, and to the U. S. West Coast.

In 1948, the Philopon trademark came under a well-publicized lawsuit by Philips Corporation. Philips, under its Koninklijke division, filed suit against Dainippon Pharmaceuticals to cease using Philipon as the commercial name for methamphetamine. Philips claimed the exclusive right to use the trademark as a portmanteau of Philips and Nippon, the Japanese name of the country. DSP's attorneys challenged Philips' standing to sue as a foreign (Dutch) corporation. The matter was ultimately settled out of court in 1952, with Dainippon Pharmaceuticals agreeing to pay Philips a 5% royalty on worldwide sales of methamphetamines sold by DSP under the Philopon label. The Japanese Ministry of Health banned production less than a year later.

In the 1950s, there was a rise in the legal prescription of methamphetamine to the American public. In the 1954 edition of Pharmacology and Therapeutics, conditions treatable by methamphetamine included "narcolepsy, postencephalitic parkinsonism, alcoholism, certain depressive states, and in the treatment of obesity." Methamphetamine constituted half of the amphetamine salts for the original formulation for the diet drug Obetrol, which later became the ADHD drug Adderall. Methamphetamine was also marketed for sinus inflammation or for non-medicinal purposes as "pep pills" or "bennies".

Recreational use and prohibitive regulations

In 1950 the Japanese Ministry of Health banned stimulant production, but drug companies continued to produce stimulants and they wound up on the black market. From 1951 to 1954 a series of acts were passed by the Japanese government to try to stop production and sale of stimulants; however, the production and sale of stimulant drugs continued through criminal syndicates such as Yakuza criminal organizations. On the streets, it is also known as S, Shabu, and Speed, in addition to its old trademarked name.

The 1960s saw the start of significant use of clandestinely manufactured methamphetamine, most of which was produced by motorcycle gangs. It was also prescribed by San Franciscan drug clinics to treat heroin addiction. Beginning in the 1990s, the production of methamphetamine in users' own homes for personal and recreational use became popular.

In 1970, methamphetamine was regulated in the Controlled Substances Act in the U. S., and a public education campaign was mounted against it.

By the 2000s, the only two FDA approved marketing indications remaining for methamphetamine were for attention-deficit hyperactivity disorder (ADHD) and the short-term management of exogenous obesity, although the drug is clinically established as effective in the treatment of narcolepsy.

Current status

The production, distribution, sale, and possession of methamphetamine is restricted or illegal in many jurisdictions. Methamphetamine has been placed in Schedule II of the United Nations Convention on Psychotropic Substances treaty.

North Korea

North Korea might be facing one of the world's worst meth epidemics. Although the secrecy of the North Korean government means that any report may be only approximate, there have been an increasing number of signs that meth is very widespread throughout the country, used both recreationally and as medicine. Methamphetamine is called Bingdu (Korean: 빙두; Hanja: 氷毒; "ice poison") in the Korean language.

United States

In 1983, laws were passed in the United States prohibiting possession of precursors and equipment for methamphetamine production. This was followed a month later by a bill passed in Canada enacting similar laws. In 1986, the U.S. government passed the Federal Controlled Substance Analogue Enforcement Act in an attempt to curb the growing use of designer drugs. Despite this, use of methamphetamine expanded from its initial base in California throughout the rural United States, especially through the Midwest and South. Government officials in many U.S. counties now report that meth is their most serious drug problem. Meth use is said to be particularly common in the American western states, where the substance is in high demand. States like Montana, South Dakota, Idaho, Colorado and Arizona have all launched extensive efforts – both private and public – to stop meth use.

Illicit production

Synthesis

Methamphetamine is most structurally similar to methcathinone and amphetamine. Synthesis is relatively simple, but entails risk with flammable and corrosive chemicals, particularly the solvents used in extraction and purification; therefore, illicit production is often discovered by fires and explosions caused by the improper handling of volatile or flammable solvents. The six major routes of production begin with either phenyl-2-propanone (P2P) or with one of the isomeric compounds pseudoephedrine and ephedrine.

One procedure uses the reductive amination of phenyl-2-propanone (phenylacetone) with methylamine, P2P was usually obtained from phenylacetic acid and acetic anhydride, though many other methods have been considered, and phenylacetic acid might arise from benzaldehyde, benzylcyanide, or benzylchloride. Methylamine is crucial to all such methods, and is produced from the model airplane fuel nitromethane, or formaldehyde and ammonium chloride, or methyl iodide with hexamine. This was once the preferred method of production by motorcycle gangs in California, until DEA restrictions on the chemicals made the process difficult. Pseudoephedrine, ephedrine, phenylacetone, and phenylacetic acid are currently DEA list I and acetic anhydride is list II on the DEA list of chemicals subject to regulation and control measures. This method can involve the use of mercuric chloride and leaves behind mercury and lead environmental wastes. The methamphetamine produced by this method is racemic, consisting partly of the unsought levomethamphetamine isomer.

The alternative Leuckart route also relies on P2P to produce a racemic product, but proceeds via methylformamide in formic acid to an intermediate N-formyl-methamphetamine, which is then decarboxylated with hydrochloric acid.

Two infrequently used reductive amination routes have also been reported. The "nitropropene route", in which benzaldehyde is condensed with nitroethane to produce 1-phenyl-2-nitropropene, which is subsequently reduced by hydrogenation of the double bond and reduction of the nitro group using hydrogen over a palladium catalyst or lithium aluminum hydride. The "oxime route" reacts phenyl-2-propanol with hydroxylamine to produce an oxime intermediate which likewise is hydrogenated using hydrogen over a palladium catalyst or lithium aluminum hydride.

Illicit methamphetamine is more commonly made by the reduction of ephedrine or pseudoephedrine, which produces the more active d-methamphetamine isomer. The maximum conversion rate for ephedrine and pseudoephedrine is 92%, although typically, illicit methamphetamine laboratories convert at a rate of 50% to 75%. Most methods of illicit production involve protonation of the hydroxyl group on the ephedrine or pseudoephedrine molecule.

Though dating back to the discovery of the drug, the Nagai route did not become popular among illicit manufacturers until ca. 1982, and comprised 20% of production in Michigan in 2002 It involves red phosphorus and hydrogen iodide (also known as hydroiodic acid or iohydroic acid). (The hydrogen iodide is replaced by iodine and water in the "Moscow route") The hydrogen iodide is used to reduce either ephedrine or pseudoephedrine to methamphetamine. On heating the precursor is rapidly iodinated by the hydrogen iodide to form iodoephedrine. The phosphorus assists in the second step, by consuming iodine to form phosphorus triiodide (which decomposes in water to phosphorous acid, regenerating hydrogen iodide). Because hydrogen iodide exists in a chemical equilibrium with iodine and hydrogen, the phosphorus reaction shifts the balance toward hydrogen production when iodine is consumed. In Australia, criminal groups have been known to substitute "red" phosphorus with either hypophosphorous acid or phosphorous acid (the "Hypo route"). This is a hazardous process for amateur chemists because phosphine gas, a side-product from in situ hydrogen iodide production, is extremely toxic to inhale. The reaction can also create toxic, flammable white phosphorus waste. Methamphetamine produced in this way is usually more than 95% pure.

The conceptually similar Emde route involves reduction of ephedrine to chloroephedrine using thionyl chloride (SOCl₂), followed by catalytic hydrogenation. The catalysts for this reaction are palladium or platinum. The Rosenmund route also uses hydrogen gas and a palladium catalyst poisoned with barium sulfate (Rosenmund reduction), but uses perchloric acid instead of thionyl chloride.

The Birch reduction, also called the "Nazi method", became popular in the mid-to-late 1990s and comprised the bulk of methamphetamine production in Michigan in 2002. It reacts pseudoephedrine with liquid anhydrous ammonia and an alkali metal such as sodium or lithium. The reaction is allowed to stand until the ammonia evaporates. However, the Birch reduction is dangerous because the alkali metal and ammonia are both extremely reactive, and the temperature of liquid ammonia makes it susceptible to explosive boiling when reactants are added. It has been the most popular method in Midwestern states of the U. S. because of the ready availability of liquid ammonia fertilizer in farming regions.

In recent years, a simplified "Shake 'n Bake" one-pot synthesis has become more popular. The method is suitable for such small batches that pseudoephedrine restrictions are less effective, it uses chemicals that are easier to obtain (though no less dangerous than traditional methods), and it is so easy to carry out that some addicts have made the drug while driving. It involves placing crushed pseudoephedrine tablets into a nonpressurized container containing ammonium nitrate, water, and a hydrophobic solvent such as Coleman fuel or automotive starting fluid, to which lye and lithium (from lithium batteries) is added. Hydrogen chloride gas produced by a reaction of salt with sulfuric acid is then used to recover crystals for purification. The container needs to be "burped" periodically to prevent failure under accumulating pressure, as exposure of the lithium to the air can spark a flash fire; thus an abandoned reaction becomes a severe hazard to firefighters. The battery lithium can react with water to shatter a container and potentially start a fire or explosion.

Producing methamphetamine in this fashion can be extremely dangerous and has been linked to several fatalities. Because users frequently carry out the reaction in a two-liter bottle held close to their bodies, which can explode if the cap is removed too soon or if it accidentally perforates, the procedure has led to a large number of severe burns — for example, approximately 70 in Indiana during 2010 and 2011. As 90% of these cases in the United States lack health insurance, and the average cost for their treatment is $130,000 (60% more than the average), which is only partially compensated by Medicaid, this method of synthesis has been blamed for the closure of hospital burn units and a cost to taxpayers of tens or hundreds of millions of dollars.

Production and distribution

Until the early 1990s, methamphetamine for the U.S. market was made mostly in labs run by drug traffickers in Mexico and California. Indiana state police found 1,260 labs in 2003, compared to just 6 in 1995, although this may be partly a result of increased police activity. As of 2007, drug and lab seizure data suggests that approximately 80 percent of the methamphetamine used in the United States originates from larger laboratories operated by Mexican-based syndicates on both sides of the border and that approximately 20 percent comes from small toxic labs (STLs) in the United States.

Mobile and motel-based methamphetamine labs have caught the attention of both the U. S. news media and the police. Such labs can cause explosions and fires and expose the public to hazardous chemicals. Those who manufacture methamphetamine are often harmed by toxic gases. Many police departments have specialized task forces with training to respond to cases of methamphetamine production. The National Drug Threat Assessment 2006, produced by the Department of Justice, found "decreased domestic methamphetamine production in both small and large-scale laboratories", but also that "decreases in domestic methamphetamine production have been offset by increased production in Mexico." The report concluded that "methamphetamine availability is not likely to decline in the near term. "

Methamphetamine labs can give off noxious fumes, such as phosphine gas, methylamine gas, solvent vapors, acetone or chloroform, iodine vapors, white phosphorus, anhydrous ammonia, hydrogen chloride/muriatic acid, hydrogen iodide, lithium and sodium gases, ether, or methamphetamine vapors. If performed by amateurs, manufacturing methamphetamine can be extremely dangerous. If the red phosphorus overheats, because of a lack of ventilation, phosphine gas can be produced. This gas is highly toxic and, if present in large quantities, is likely to explode upon autoignition from diphosphine, which is formed by overheating phosphorus.

In July 2007, Mexican officials at the port of Lázaro Cárdenas seized a ship carrying 19 tons of pseudoephedrine, a raw material needed for methamphetamine. The shipment originated in Hong Kong and passed through the United States at the port of Long Beach prior to its arrival in Mexico.

The Australian Crime Commission's illicit drug data report for 2011–2012 was released in western Sydney, Australia on 20 May 2013 and revealed that the average strength of crystal methamphetamine doubled in most Australian jurisdictions within a 12-month period and the majority of domestic laboratory closures involved small "addict-based" operations.

Impurities and adulterants

In Japan, methamphetamine seizures are usually white crystals of high purity, but contain impurities that vary according to the means of production, and are sometimes adulterated.

Diagnostic impurities are the naphthalenes 1-benzyl-methylnaphthalene and 1,3-dimethyl-2-phenylnaphthalene, arising in the Nagai and Leuckart routes, and cis- or trans- 1,2-dimethyl-3-phenylaziridine, ephedrine, or erythro-3,4-dimethyl- 5-phenyloxazolidine, arising in the Nagai and Emde routes; these are absent in the reductive amination route. Characteristic impurities of the Birch route include N-methyl-1-(1-(1,4-cyclohexadienyl))-2-propanamine. Methamphetamine produced by the Birch route contains phenyl-2-propanone, the precursor for the reductive amination route, as a degradation product. However, specific diagnostic impurities are not very reliable in practice, and it is generally preferable for forensic technicians to evaluate a larger profile of trace compounds.

A common adulterant is dimethyl sulfone, a solvent and cosmetic base without known effect on the nervous system; other adulterants include dimethylamphetamine HCl, ephedrine HCl, sodium thiosulfate, sodium chloride, sodium glutamate, and a mixture of caffeine with sodium benzoate.

In the United States, illicit methamphetamine comes in a variety of forms with prices varying widely over time. Most commonly, it is found as a colorless crystalline solid. Impurities may result in a brownish or tan color. Colorful flavored pills containing methamphetamine and caffeine are known as yaa baa (Thai for "crazy medicine").

An impure form of methamphetamine is sold as a crumbly brown or off-white rock, commonly referred to as "peanut butter crank". It may be diluted or cut with non-psychoactive substances like inositol, isopropylbenzylamine or dimethylsulfone. Another popular method is to combine methamphetamine with other stimulant substances, such as caffeine or cathine, into a pill known as a "Kamikaze", which can be particularly dangerous due to the synergistic effects of multiple stimulants. Reports in 2007 of the appearance of flavored "Strawberry Quik meth" circulated in the media and local law enforcement, but were debunked in 2010 by the DEA, although meth of varying colors has been seized.

Rarely, the impure reaction mixture from the hydrogen iodide/red phosphorus route is used without further modification, usually by injection; it is called "ox blood". "Meth oil" refers to the crude methamphetamine base produced by several synthesis procedures. Ordinarily it is purified by exposure to hydrogen chloride, as a solution or as a bubbled gas, and extraction of the resulting salt occurs by precipitation and/or recrystallization with ether/acetone.

Slang terms

Slang terms for methamphetamine, especially common among illicit users, are numerous and vary from region to region. Some names are "crystal meth", "meth", "speed", "crystal", "clavo", "ice", "shards", "shabu/shaboo", "glass", "jib", "crank", "batu/batunas", "scanté", "schizznit", "gack", "tweak", "rizz", "rock", "tina" and "cold". Some terms vary by region or subculture.

Some regional terms are based on the original trade names; thus "필로폰" ("Pilopon") in South Korea, "Пико" for pure methamphetamine in Bulgaria or "piko" in the Czech Republic, Slovakia, and Poland after the trade name "Pervitin". Also "peří" ("feathers", phonetically similar to "Pervitin") and "perník" ("gingerbread", phonetically similar to "Pervitin" in the Czech Republic. In New Zealand it is called "P".

Other local names include “冰毒” (Bīng Dú, Chinese for "Ice drug") in China, "ya ba" (Thai for "Crazy Medicine", Thailand), "ya ice" (Thai for "Ice drug", Thailand), "đá" (Vietnamese for "ice", Vietnam), "batu kilat" (Malaysian for "shining rocks", Malaysia), "bato" (Filipino for "rock" or "stone", Philippines) "شیشه" (in translation "Glass", transliterate to "Shishe", Iran), "tik" (South Africa), "dimineata speciala aurie" ("Special golden morning", Romania), "bala" in Brazilian Portuguese, "tjäck" in Swedish, "ספיד" in Israel and "Teeft" United Kingdom.

"Vint", Russian for "a screw", specifically refers to a very impure homemade form of methamphetamine in Russia. The name originally comes from "Pervitin," a pharmaceutical trademark.

See also

• Breaking Bad - An award winning television series involving the criminal production of methamphetamine
• Faces of Meth
• Montana Meth Project
• Rolling meth lab

Notes

• Yudko, Errol (2008-10-29). Methamphetamine Use: Clinical and Forensic Aspects. 408 (2nd ed.). Boca Raton, FL: CRC Press. ISBN 978-0-8493-7273-5. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)

The DSM IV has amphetamine defined in two ways: Amphetamine dependence (304.40) and Amphetamine abuse (305.70)

References

1. ^ Schep LJ, Slaughter RJ, Beasley DM (2010). "The clinical toxicology of metamfetamine". Clinical Toxicology (Philadelphia, Pa.). 48 (7): 675–94. doi:10.3109/15563650.2010.516752. ISSN 1556-3650. PMID 20849327. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
2. "Methamphetamine". Drug profiles. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 16 August 2010. Retrieved 1 September 2011.
3. "Ice facts". Drug facts. Australian Drug Foundation (ADF). 18 January 2012. Retrieved 23 November 2012.
4. ^ Covey, Herbert C. (2007). The Methamphetamine Crisis: Strategies to Save Addicts, Families, And Communities. Greenwood Publishing Group. p. 9. ISBN 0-275-99322-1.
5. Amphetamines: Advances in Research and Application: 2011 Edition. ScholarlyEditions. 2012. p. 2. ISBN 1-464-92805-3.
6. Castle, L; Aubert, RE; Verbrugge, RR; Khalid, M; Epstein, RS (2007). "Trends in medication treatment for ADHD". Journal of Attention Disorders. 10 (4): 335–342. doi:10.1177/1087054707299597. PMID 17449832. {{cite journal}}: Unknown parameter |month= ignored (help)
7. ^ "List of psychotropic substances under international control" (PDF). International Narcotics Control Board. Retrieved 2010-05-10.
8. http://www.oehha.org/public_info/pdf/TSD%20Methamphetamine%20Meth%20Labs%2010'8'03.pdf
9. Mack, Avram H.; Frances, Richard J.; Miller, Sheldon I. (2005). Clinical Textbook of Addictive Disorders, Third Edition. New York: The Guilford Press. p. 207. ISBN 1-59385-174-X.{{cite book}}: CS1 maint: multiple names: authors list (link)
10. B. K. Logan. Methamphetamine – Effects on Human Performance and Behavior. Forensic Science Review, Vol. 14, no. 1/2 (2002), p. 142 Full PDF
11. ^ Cruickshank, CC.; Dyer, KR. (2009). "A review of the clinical pharmacology of methamphetamine". Addiction. 104 (7): 1085–99. doi:10.1111/j.1360-0443.2009.02564.x. PMID 19426289. {{cite journal}}: Unknown parameter |month= ignored (help)
12. ^ Darke, S.; Kaye, S.; McKetin, R.; Duflou, J. (2008). "Major physical and psychological harms of methamphetamine use". Drug Alcohol Rev. 27 (3): 253–62. doi:10.1080/09595230801923702. PMID 18368606. {{cite journal}}: Unknown parameter |month= ignored (help)
13. ^ "Desoxyn (Methamphetamine Hydrochloride) Drug Information: User Reviews, Side Effects, Drug Interactions and Dosage at". Rxlist.com. Retrieved 2011-01-09.
14. "Desoxyn". Lundbeck. Retrieved 2012-12-18.
15. ^ Mitler MM, Hajdukovic R, Erman MK (1993). "Treatment of narcolepsy with methamphetamine". Sleep. 16 (4): 306–17. PMC 2267865. PMID 8341891. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
16. Mohler (2006-04-01). Advanced Therapy In Hypertension And Vascular Disease. PMPH-USA. p. 469. ISBN 978-1-55009-318-6. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
17. "Are there any effective treatments for methamphetamine abusers?". The Methamphetamine Problem: Question-and-Answer Guide. Tallahassee: Institute for Intergovernmental Research. 2009. Retrieved 2009-08-13.
18. "Physiological Effects of a Methamphetamine Overdose | Montana State University". Montana.edu. Retrieved 2011-01-09.
19. ^ "Erowid Methamphetamine Vault: Effects". Erowid.org. Retrieved 2011-01-09.
20. Dart, Richard (2004). Medical Toxicology. Lippincott Williams & Wilkins. p. 1074. ISBN 978-0-7817-2845-4.
21. "What are the signs that a person may be using methamphetamine?". The Methamphetamine Problem: Question-and-Answer Guide. Tallahassee: Institute for Intergovernmental Research. 2009. Retrieved 2009-08-13.
22. "Methamphetamine Effects: Including Long Term". KCI — The Anti-Meth Site. Retrieved 2011-01-09.
23. "Methamphetamine medical facts from". Drugs.com. Retrieved 2011-01-09.
24. "Methamphetamine | Center for Substance Abuse Research (CESAR)". Cesar.umd.edu. Retrieved 2011-01-09.
25. "Amphetamines: Drug Use and Dependence | Merck Manual Professional". Merck.com. Retrieved 2011-01-09.
26. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM (2005). "The nature, time course and severity of methamphetamine withdrawal". Addiction. 100 (9): 1320–9. doi:10.1111/j.1360-0443.2005.01160.x. PMID 16128721. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
27. Thrash, B.; Thiruchelvan, K.; Ahuja, M.; Suppiramaniam, V.; Dhanasekaran, M. (2009). "Methamphetamine-induced neurotoxicity: the road to Parkinson's disease" (PDF). Pharmacol Rep. 61 (6): 966–77. PMID 20081231. {{cite journal}}: Cite has empty unknown parameter: |month= (help)
28. Krasnova, I.N.; Cadet, J.L. (2009). "Methamphetamine toxicity and messengers of death". Brain Res Rev. 60 (2): 379–407. doi:10.1016/j. brainresrev.2009.03.002. PMC 2731235. PMID 19328213. {{cite journal}}: Check |doi= value (help); Unknown parameter |month= ignored (help)
29. Barr, AM.; Panenka, WJ.; MacEwan, GW.; Thornton, AE.; Lang, DJ.; Honer, WG.; Lecomte, T. (2006). "The need for speed: an update on methamphetamine addiction". J Psychiatry Neurosci. 31 (5): 301–13. PMC 1557685. PMID 16951733. {{cite journal}}: Unknown parameter |month= ignored (help)
30. ^ Ghodse, Hamid (2002-08-15). Drugs and Addictive Behaviour: A Guide to Treatment. Cambridge University Press. p. 114. ISBN 978-0-521-00001-7.
31. Bennett, B.A.; Hollingsworth, C.K.; Martin, R.S.; Harp, J.J. (1998). "Methamphetamine-induced alterations in dopamine transporter function". Brain Research. 782 (1–2): 219–27. doi:10.1016/S0006-8993(97)01281-X. PMID 9519266. {{cite journal}}: Unknown parameter |month= ignored (help)
32. You Know... Methamphetamine. Centre for Addiction and Mental Health.
33. Adam M. Leventhal (2008). "Anhedonia and Amotivation in Psychiatric Outpatients with Fully Remitted Stimulant Use Disorder". Am J Addict. 17 (3): 218–223. doi:10.1080/10550490802019774. PMC 2650808. PMID 18463999.
34. Wagner GC, Carelli RM, Jarvis MF (1985). "Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats". Research Communications in Chemical Pathology and Pharmacology. 47 (2): 221–8. PMID 3992009. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
35. Wagner GC, Carelli RM, Jarvis MF (1986). "Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion". Neuropharmacology. 25 (5): 559–61. doi:10.1016/0028-3908(86)90184-X. PMID 3488515. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
36. Oyler JM, Cone EJ, Joseph RE, Moolchan ET, Huestis MA (2002). "Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of methamphetamine to humans". Clinical Chemistry. 48 (10): 1703–14. PMID 12324487. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
37. The Ice Age (See Below)
38. Rothman RB, Partilla JS, Baumann MH, Dersch CM, Carroll FI, Rice KC (2000). "Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse". Synapse. 35 (3): 222–7. doi:10.1002/(SICI)1098-2396(20000301)35:3<222::AID-SYN7>3.0.CO;2-K. PMID 10657029. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
39. ^ Winslow BT, Voorhees KI, Pehl KA (2007). "Methamphetamine abuse". American Family Physician. 76 (8): 1169–74. PMID 17990840.{{cite journal}}: CS1 maint: multiple names: authors list (link)
40. Grabowski J, Shearer J, Merrill J, Negus SS (2004). "Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence". Addictive Behaviors. 29 (7): 1439–64. doi:10.1016/j. addbeh.2004.06.018. PMID 15345275. {{cite journal}}: Check |doi= value (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
41. "Sleep medicine 'can help ice addicts quit'". Retrieved 2007-12-02.
42. "Medication can help recovering meth addicts stay sober, study finds". Retrieved 2012-06-13.
43. AJ Giannini. Drugs of Abuse—Second Edition. Los Angeles, Practice Management Information Company, 1997.
44. "Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis". Amphetamines.com. Retrieved 2011-01-09.
45. "Methamphetamine Use (Meth Mouth)". American Dental Association. Archived from the original on 2008-06-01. Retrieved 2006-12-16.
46. "Meth Mouth | Meth awareness and prevention project of South Dakota". Mappsd.org. Retrieved 2011-11-26.
47. Hasan AA, Ciancio S (2004). "Relationship between amphetamine ingestion and gingival enlargement". Pediatric Dentistry. 26 (5): 396–400. PMID 15460293.
48. Shaner JW (2002). "Caries associated with methamphetamine abuse". The Journal of the Michigan Dental Association. 84 (9): 42–7. PMID 12271905. {{cite journal}}: Unknown parameter |month= ignored (help)
49. "Acute Public Health Consequences of Methamphetamine Laboratories | Centers for Disease Control & Prevention (CDC)". Cdc.gov. Retrieved 2011-01-09.
50. "How to avoid buying a meth house". MSN Real Estate. Retrieved 2011-08-16.
51. "Health Consultation" (PDF). Agency for Toxic Substances & Disease Registry (ATSDR). Retrieved 2011-01-09.
52. Chomchai C, Na Manorom N, Watanarungsan P, Yossuck P, Chomchai S (2010-12-08). "Methamphetamine abuse during pregnancy and its health impact on neonates born at Siriraj Hospital, Bangkok, Thailand. | PubMed". Southeast Asian J. Trop. Med. Public Health. 35 (1): 228–31. PMID 15272773.{{cite journal}}: CS1 maint: multiple names: authors list (link)
53. "Up to 20 per cent of gay men have tried crystal meth". PinkNews. 2006-07-14. Retrieved 2011-01-09.
54. Halkitis PN, Pandey Mukherjee P, Palamar JJ (2008). "Longitudinal Modeling of Methamphetamine Use and Sexual Risk Behaviors in Gay and Bisexual Men". AIDS and Behavior. 13 (4): 783–791. doi:10.1007/s10461-008-9432-y. PMID 18661225.{{cite journal}}: CS1 maint: multiple names: authors list (link)
55. Patrick Moore (2005-06-14). "We Are Not OK". VillageVoice. Retrieved 2011-01-09.
56. "Methamphetamine Use and Health | UNSW: The University of New South Wales – Faculty of Medicine" (PDF). Retrieved 2011-01-09.
57. ^ "Properties and effects of methamphetamine | Turning Point Alcohol and Drug Centre" (PDF). Retrieved 2011-01-09.
58. Schepers RJ, Oyler JM, Joseph RE, Cone EJ, Moolchan ET, Huestis MA (2003). "Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers". Clinical Chemistry. 49 (1): 121–32. doi:10.1373/49.1.121. PMID 12507968. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
59. Hendrickson H, Laurenzana E, Owens SM (2006). "Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection". The AAPS Journal. 8 (4): E709–17. doi:10.1208/aapsj080480. PMC 2751367. PMID 17233534.{{cite journal}}: CS1 maint: multiple names: authors list (link)
60. Marsel J, Döring G, Remberg G, Spiteller G (1972). "Methamphetamine--a metabolite of the anorectics Benzphetamine and Furfenorex". Zeitschrift für Rechtsmedizin. Journal of legal medicine. 70 (4): 245–50. doi:10.1007/BF02079690. PMID 5084766. {{cite journal}}: Cite has empty unknown parameter: |month= (help)CS1 maint: multiple names: authors list (link)
61. Greenhill B, Valtier S, Cody JT (2003). "Metabolic profile of amphetamine and methamphetamine following administration of the drug famprofazone". Journal of analytical toxicology. 27 (7): 479–84. PMID 14607003. {{cite journal}}: Cite has empty unknown parameter: |month= (help)CS1 maint: multiple names: authors list (link)
62. "Drugs and Human Performance FACT SHEETS – Methamphetamine (and amphetamine) | National Highway Traffic Safety Administration (NHTSA)". Nhtsa.gov. Retrieved 2011-01-09.
63. National Highway Traffic Safety Administration (NHTSA) - Methamphetamine (And Amphetamine)
64. de la Torre R, Farré M, Navarro M, Pacifici R, Zuccaro P, Pichini S. Clinical pharmacokinetics of amphetamine and related substances: monitoring in conventional and non-conventional matrices. Clin. Pharmacokinet. 43: 157-185, 2004.
65. Paul BD, Jemionek J, Lesser D, Jacobs A, Searles DA. Enantiomeric separation and quantitation of (+/-)-amphetamine, (+/-)-methamphetamine, (+/-)-MDA, (+/-)-MDMA, and (+/-)-MDEA in urine specimens by GC-EI-MS after derivatization with (R)-(-)- or (S)-(+)-alpha-methoxy-alpha-(trifluoromethy)phenylacetyl chloride (MTPA). J. Anal. Toxicol. 28: 449-455, 2004.
66. R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 9th edition, Biomedical Publications, Seal Beach, CA, 2011, pp. 1027-1030.
67. Venkatratnam, Abhishek (2011). "Zinc Reduces the Detection of Cocaine, Methamphetamine, and THC by ELISA Urine Testing". Journal of Analytical Toxicology. 35 (6): 333–340. doi:10.1093/anatox/35.6.333. PMID 21740689. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
68. Rothman, et al. "Amphetamine-Type Central Nervous System Potently than they Release Dopamine and Serotonin. " (2001): Synapse 39, 32-41 (Table V. on page 37)
69. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 19364908, please use {{cite journal}} with |pmid=19364908 instead.
70. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 11723224, please use {{cite journal}} with |pmid=11723224 instead.
71. Itzhak Y, Martin JL, Ali SF (2002). "Methamphetamine-induced dopaminergic neurotoxicity in mice: long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine". Progress in Neuro-psychopharmacology & Biological Psychiatry. 26 (6): 1177–83. doi:10.1016/S0278-5846(02)00257-9. PMID 12452543. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
72. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001). "Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment". Brain Research. Brain Research Reviews. 36 (1): 1–22. doi:10.1016/S0165-0173(01)00054-6. PMID 11516769. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
73. Yamamoto BK, Zhu W (1998). "The effects of methamphetamine on the production of free radicals and oxidative stress". The Journal of Pharmacology and Experimental Therapeutics. 287 (1): 107–14. PMID 9765328. {{cite journal}}: Unknown parameter |month= ignored (help)
74. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 12843288, please use {{cite journal}} with |pmid=12843288 instead.
75. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 19409267, please use {{cite journal}} with |pmid=19409267 instead.
76. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 12388602, please use {{cite journal}} with |pmid=12388602 instead.
77. Reese EA, Bunzow JR, Arttamangkul S, Sonders MS, Grandy DK (2007). "Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine". The Journal of Pharmacology and Experimental Therapeutics. 321 (1): 178–86. doi:10.1124/jpet.106.115402. PMID 17218486. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
78. Grandy DK (2007). "Trace amine-associated receptor 1-Family archetype or iconoclast?". Pharmacology & Therapeutics. 116 (3): 355–90. doi:10.1016/j.pharmthera.2007.06.007. PMC 2767338. PMID 17888514. {{cite journal}}: Unknown parameter |month= ignored (help)
79. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, Gerald C (2001). "Trace amines: identification of a family of mammalian G protein-coupled receptors". Proc. Natl. Acad. Sci. U. S. A. 98 (16): 8966–71. doi:10.1073/pnas.151105198. PMC 55357. PMID 11459929.{{cite journal}}: CS1 maint: multiple names: authors list (link)
80. ^ Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DK (2001). "Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor". Mol. Pharmacol. 60 (6): 1181–8. PMID 11723224. {{cite journal}}: Unknown parameter |unused_data= ignored (help)CS1 maint: multiple names: authors list (link)
81. Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, Frascarelli S, Crossley DA, Bunzow JR, Ronca-Testoni S, Lin ET, Hatton D, Zucchi R, Grandy DK (2004). "3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone". Nat. Med. 10 (6): 638–42. doi:10.1038/nm1051. PMID 15146179.{{cite journal}}: CS1 maint: multiple names: authors list (link)
82. Liberles SD, Buck LB (2006). "A second class of chemosensory receptors in the olfactory epithelium". Nature. 442 (7103): 645–50. doi:10.1038/nature05066. PMID 16878137.
83. Yuan J, Hatzidimitriou G, Suthar P, Mueller M, McCann U, Ricaurte G (2006). "Relationship between temperature, dopaminergic neurotoxicity, and plasma drug concentrations in methamphetamine-treated squirrel monkeys". The Journal of Pharmacology and Experimental Therapeutics. 316 (3): 1210–8. doi:10.1124/jpet.105.096503. PMID 16293712. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
84. BA Clement, CM Goff, TDA Forbes, Phytochemistry Vol.49, No 5, pp 1377–1380 (1998) "Toxic amines and alkaloids from Acacia rigidula"
85. "Ask Dr. Shulgin Online: Acacias and Natural Amphetamine". Cognitiveliberty.org. 2001-09-26. Retrieved 2011-01-09.
86. Siegler, D. S. (2003). "Phytochemistry of Acacia—sensu lato". Biochemical Systematics and Ecology. 31 (8): 845–873. doi:10.1016/S0305-1978(03)00082-6. {{cite journal}}: Unknown parameter |month= ignored (help)
87. "Journal of Pharmacology and Experimental Therapeutics (JPET) | Onset of Action and Drug Reinforcement" (PDF). Retrieved 2011-01-09.
88. "Methamphetamine | Abstemious Outpatient Clinic, Inc". Abstemious.org. Retrieved 2011-11-26.
89. "Methamphetamine: One of America's Greatest Challenges Part I | University of Nebraska-Lincoln" (PDF). Retrieved 2011-11-26.
90. "Smoking Meth, the beginner and expert guide to chase the white dragon". Smokingmeth.Net. 2010-04-24. Retrieved 2011-11-26.
91. "Heroin: a history of chasing the dragon". Biopsychiatry.com. Retrieved 2012-01-29.
92. "Methamphetamine Toxicity Secondary to Intravaginal Body Stuffing | University of Hawaii System" (PDF). Retrieved 2011-11-26.
93. "Short Term Effects of Smoking Crystal Meth | LoveToKnow Recovery". Addiction. lovetoknow.com. Retrieved 2011-01-09.
94. ^ "National Drug Strategy - 1.9 Routes of administration | Department of Health and Ageing". Health.gov.au. Retrieved 2011-11-26.
95. "Meth Facts". All Treatment. Retrieved 2011-11-26.
96. "Ascorbic acid-deficient condition alters central effects of methamphetamine". ScienceDirect. Retrieved 2011-11-26.
97. "Urban Dictionary". Urban Dictionary. Retrieved 2011-11-26.
98. ^ "Historical overview of methamphetamine". Vermont Department of Health. Retrieved 2012-01-29.
99. "The pH Levels of Different Methamphetamine Drug Samples on the StreetMarket in Cape Town", p.1, 2011, A. Bardow, Oral & Dental Research Institute, Faculty of Dentistry, University of the Western Cape
100. Grinspoon (1975-01-01). Speed Culture: Amphetamine Use and Abuse in America. Harvard University Press. p. 18. ISBN 978-0-674-83192-6. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
101. ^ "Methamphetamine" (PDF). EMCDDA.
102. Andreas Ulrich, Andreas. "The Nazi Death Machine: Hitler's Drugged Soldiers – SPIEGEL ONLINE – News – International". Spiegel Online. Retrieved 2009-11-17.
103. "The History of Crystal Meth". Addictionsearch. Retrieved 21 November 2012.
104. Adam Tooze (2007). [[The Wages of Destruction]]: The Making and Breaking of the Nazi Economy. London, UK: Penguin Books. Retrieved 21 November 2012. {{cite book}}: URL–wikilink conflict (help)
105. Andreas Ulrich (2005-05-06). "Hitler's Drugged Soldiers". Der Spiegel.
106. Doyle, D (2005). "Hitler's Medical Care" (PDF). Journal of the Royal College of Physicians of Edinburgh. 35 (1): 75–82. PMID 15825245. Retrieved 2006-12-28.
107. Google Translate.
108. Romaji Translator at Romaji.org.
109. John Philip Jenkins. "methamphetamine (drug) - Britannica Online Encyclopedia". Britannica.com. Retrieved 2012-01-29.
110. Greg Miller (2003-01-04). "'Go' pills for F-16 pilots get close look: Amphetamines prescribed in mission that killed Canadians". Los Angeles Times.
111. ^ Digital Creators Studio Yama-Arashi (2006-04-16). "抗うつ薬いろいろ (Various Antidepressants)". 医療情報提供サービス (in Japanese). Archived from the original on 2007-12-21. Retrieved 2006-07-14. Cite error: The named reference "Philopon" was defined multiple times with different content (see the help page).
112. ^ Tamura, M. (1989-01-01). "Japan: stimulant epidemics past and present". Bulletin on Narcotics. United Nations Office on Drugs and Crime. pp. 83–93. Retrieved 14 July 2006.
113. Grollman, Arthur (1954). Pharmacology and Therapeutics: a Textbook for Students and Practitioners of Medicine. Lea & Febiger. p. 209. ISBN 0-8121-0105-7. {{cite book}}: Cite has empty unknown parameter: |coauthors= (help)
114. Stone Fish, Isaac (20 June 2011). "North Korea's Addicting Export: Crystal Meth". Pulitzer Center on Crisis Reporting. Retrieved 2011-06-27.
115. Cho Jong Ik (2011-05-23). "'Bingdu' Prevalence Difficult to Grasp". Daily NK. Retrieved 22 October 2011.
116. The Gazette Staff (6 Oct 2009). "Anhydrous ammonia tank locks have flaws". Cedar Rapids Gazette.
117. "Methamphetamine Use: Lessons Learned" (PDF). National Criminal Justice Reference Service (NCJRS). Retrieved 2011-01-09.
118. Roots, Roger (5 April 2011). "Cooking Meth: How Government Manufactured a Drug Epidemic". LewRockwell.com. {{cite web}}: Italic or bold markup not allowed in: |publisher= (help)
119. ^ B. Remburg and A. H. Stead (1999). "Drug characterization/impurity profiling, with special focus on methamphetamine: recent work of the United Nations International Drug Control Programme". Bulletin on Narcotics (UNODC).
120. ^ Otto Snow (2002). Amphetamine syntheses. Thoth Press. ISBN 0-9663128-3-X. p. 90. Cite error: The named reference "Snow" was defined multiple times with different content (see the help page).
121. "A Synthesis of Amphetamine. J. Chem. Educ. 51, 671 (1974)". Erowid.org. Retrieved 2011-01-09.
122. Many literature citations for such examples can be found in an anonymous manuscript authored by "U. P. Yourspigs" which is archived at Erowid: "The Complete Book Of Ecstacy". {{cite web}}: |chapter= ignored (help)
123. ^ Y. Makino (2005). "Investigation of the origin of ephedrine and methamphetamine by stable isotope ratio mass spectrometry: a Japanese experience" (PDF). 52 (1–2). Bulletin on Narcotics. {{cite journal}}: Cite journal requires |journal= (help)
124. Uncle Fester. Secrets of methamphetamine manufacture (8 ed.). Festering Publications.
125. Owen, Frank (2007). "Chapter 1: The Rise of Nazi Dope". No Speed Limit: The Highs and Lows of Meth. Macmillan. pp. 17–18. ISBN 978-0-312-35616-3.
126. ^ "Types of Meth Labs". METH Awareness and Prevention Project of South Dakota.
127. National Drug Intelligence Center. "Methamphetamine". U. S. Department of Justice.
128. ^ "Recommended methods of the identification and analysis of amphetamine, methamphetamine, and their ring-substituted analogues in seized materials" (PDF). UNODC. 2006.
129. "The War on Drugs: Methamphetamine, Public Health, and Crime | University of California, Santa Cruz (UCSC)" (PDF). Retrieved 2011-01-09.
130. United Nations Office on Drugs and Crime. Laboratory and Scientific Section (2006-03-01). "nagai+route" Recommended methods for the identification and analysis of amphetamine, methamphetamine and their ring-substituted analogues in seized materials.
131. ^ Michigan Department of Community Health Under a Cooperative Agreement with Agency for Toxic Substances and Disease Registry (2004-11). "Potential Health Effects at a Clandestine Methamphetamine Laboratory using the Red Phosphorus Production Method" (PDF). {{cite web}}: Check date values in: |date= (help); line feed character in |author= at position 40 (help)
132. ^ Hiroyuki Inoue et al. (2008). "http://jhs.pharm.or.jp/data/54%286%29/54_615.pdf" (PDF). Journal of Health Science. 54 (6): 615–622. {{cite journal}}: External link in |title= (help)
133. ^ T. S. Cantrell et al. (1988-10). "A study of impurities found in methamphetamine synthesized from ephedrine". Forensic Science International. pp. 39–53. {{cite web}}: Check date values in: |date= (help) (online version, 2005, at )
134. PACIA.org.au
135. "A single step process for methamphetamine manufacture using hypophosphorus acid". Journal of the Clandestine Laboratory Investigating Chemists Association. 5: 14–15. 1995. (cited in Inoue)
136. Dominique Albouy et al. (1997-02-15). "Regenerative role of the red phosphorus in the couple 'HIaq/Pred'". 529 (1–2). Journal of Organometallic Chemistry: 295–299. doi:10.1016/S0022-328X(96)06558-8. {{cite journal}}: Cite journal requires |journal= (help) (archived online 2005 at )
137. "Skinner, H. F. (1990). "Methamphetamine Synthesis via HI/Red Phosphorus Reduction of Ephedrine". Forensic Science International. 48: 128–134. Reprinted at http://www.rhodium.ws/chemistry/meth.hi-rp.html (dead link)" (cited in )
138. Andrew Allen and Thomas S. Cantrell (1989). "Synthetic Reductions in Clandestine Amphetamine and Methamphetamine Laboratories". Forensic Science International. 42 (3): 183–199. doi:10.1016/0379-0738(89)90086-8.
139. "Illinois Attorney General | Basic Understanding Of Meth". Illinoisattorneygeneral.gov. Retrieved 2011-01-09.
140. "New 'shake-and-bake' method for making crystal meth gets around drug laws but is no less dangerous". New York Daily News. Associated Press. August 25, 2009.
141. ^ Evan Ziegelman (2011-02-03). "Meth Lab Busted on Warpath". The Columbus Packet.
142. Jay D. Michael. "Firefighting in Clandestine Drug Labs". Fire Engineering.
143. ""Shake and bake" meth technique raises concerns". YouTube. 2010-10-07. (includes Kansas state drug lab illustration of the shake-and-bake reaction)
144. "Tulsa Police Meth Explosion". YouTube. 2011-03-03.
145. "Shake and Bake Meth". Retrieved 2009-12-01. {{cite web}}: Text "New 'Shake and Bake' Meth Method Explodes" ignored (help)
146. "Meth Shakers Overwhelm Burn Units". 2013-02-23.
147. "Law Enforcement Facts". U.S.: Indiana State Government. 2007. Archived from the original on 2007-09-22. {{cite web}}: |archive-date= / |archive-url= timestamp mismatch; 2007-09-26 suggested (help)
148. DEA Congressional Testimony, "Drug Threats And Enforcement Challenges". U. S. Drug Enforcement Administration. March 22, 2007. Retrieved 2008-05-03.
149. Tiffany Craig. "Meth Explosion Caught On Tape". YouTube (WKRGNews).
150. "Methamphetamine". National Drug Intelligence Center. January 2006. Retrieved 2009-08-25. {{cite web}}: Text "National Drug Threat Assessment 2006" ignored (help)
151. Mexico says pseudoephedrine case signals breakdown in port security in U.S., China AP, The Telegram (The Canadian Press), July 26, 2007. Olga R. Rodriguez
152. MARK SCHLIEBS (20 May 2013). "Purity on the rise as ice tops the drugs wave". The Australian. Retrieved 20 May 2013.
153. "The Price and Purity of Illicit Drugs: 1981 Through the Second Quarter of 2003". WhiteHouseDrugPolicy.gov. 2004. Archived from the original on 2005-10-27. {{cite web}}: Unknown parameter |month= ignored (help)
154. Amos, Glenda (September 2007). "The Ice Epidemic" (PDF). WCTU.com.au. Australia: Woman's Christian Temperance Union. Archived from the original (PDF) on 2008-07-19. Retrieved 2010-11-17.
155. De Vries, Lloyd (May 2, 2007). "Candy Flavored Meth Targets New Users". CBS News. Retrieved 2012-08-09.
156. Mikkelson, Barbara. "Strawberry Meth". Snopes.com. Retrieved 2009-08-25.
157. Meth Slang Names
158. "What is methamphetamine? | New Zealand Police". Police.govt.nz. 2004-10-15. Retrieved 2011-01-09.
159. ^ "Meth Slang Names for Meth, Meth Jargon | Meth Addiction and Recovery". Methhelponline.com. 2007-02-09. Retrieved 2011-01-09.
160. Plüddemann, Andreas (2005-06). "Tik, memory loss and stroke". Science in Africa. South Africa: Science magazine for Africa CC. Retrieved 2009-08-13. {{cite news}}: Check date values in: |date= (help); More than one of |work= and |journal= specified (help)
161. Smirnov, Alexander (March–April, 2001). "Drugs and HIV infection in the Russian Federation". drugtext foundation. Archived from the original on 1 May 2009. Retrieved 1 September 2011. {{cite web}}: Check date values in: |date= (help)

External links

• NLM Hazardous Substances Data Bank—Entry for d-methamphetamine
• EMCDDA drugs profiles: Methamphetamine (2007)
• EMCDDA paper on Methamphetamine supply in Europe (2009)
• A Key to Methamphetamine-Related Literature—A comprehensive thematic index of methamphetamine research published in academic and scientific journals with links from citations to the PubMed abstracts.
• Poison Information Monograph (PIM 334: Methamphetamine)
• Chronic Amphetamine Use and Abuse—A thorough review on the effects of chronic use (American College of Neuropsychopharmacology)
• ChemSub Online: Methamphetamine

Documentaries

• The Ice Age by ABC Australia—Australian methamphetamine use.
• The Meth Epidemic—Frontline episode
• The World's Most Dangerous Drug—National Geographic.
• The City Addicted to Crystal Meth—BBC (Louis Theroux)
• Childhelp Crystal Darkness
• American Meth
• the fifth estate: Dark Crystal by CBC

Academic sources

• KLEE (1997). Amphetamine Misuse: International Perspectives on Current Trends. Taylor & Francis. ISBN 9789057020797.